Biotest (BIO3) AI Stock Analysis

• Market Cap: €1.33B
• Dividend Yield: 0.13%
• Average Volume (3M): 729.00
• Price to Earnings (P/E): ―
• Beta (1Y): >-0.01
• Revenue Growth: -18.82%
• EPS Growth: -113.85%
• Country: DE
• Employees: 2,495
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,785,727
• 10 Day Avg. Volume: 974
• 30 Day Avg. Volume: 729
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.29
• Revenue Forecast (FY): €613.48M

• Rating: 64 Neutral
• Price Target: €35.00 ▲(10.76% Upside)

Biotest's stock score is primarily influenced by its strong technical analysis, indicating bullish momentum and a positive trend. However, the financial performance shows some risks due to high leverage and declining net profit margins. The valuation is concerning with a negative P/E ratio, although the high dividend yield provides some compensation. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Revenue Model

Biotest's robust revenue model, focusing on essential biopharmaceutical products, ensures consistent demand and stable revenue streams.

Operational Efficiency

Improved operational efficiency, as indicated by better gross profit margins, suggests effective cost management and potential for higher profitability.

Cash Flow Improvement

Positive free cash flow indicates enhanced cash management, providing more flexibility for strategic investments and debt reduction.

Negative Factors

High Leverage

Increased leverage can strain financial stability, limiting Biotest's ability to invest in growth opportunities and increasing vulnerability to economic downturns.

Declining Net Profit Margin

A declining net profit margin reflects reduced profitability, which may hinder Biotest's ability to reinvest in business development and innovation.

Cash Conversion Challenges

Challenges in converting income into cash can impact liquidity, affecting Biotest's capacity to meet short-term obligations and invest in growth.

Biotest Business Overview & Revenue Model

Company Description

Biotest AG (BIO3) is a global biotechnology company that specializes in the development, production, and marketing of high-quality plasma proteins for the treatment of immunological and hematological disorders. The company's portfolio includes products such as immunoglobulins, clotting factors, and other plasma-derived therapies. Biotest operates in the biopharmaceutical sector and focuses on providing innovative solutions for patients with complex health conditions, leveraging advanced technologies in its manufacturing processes.

How the Company Makes Money

Biotest generates revenue primarily through the sale of its plasma-derived products, which are marketed to hospitals, clinics, and healthcare providers worldwide. The company operates a revenue model based on direct sales and distribution partnerships, ensuring a steady flow of income from both domestic and international markets. Key revenue streams include the sale of immunoglobulin products, clotting factors, and therapies for autoimmune diseases. Additionally, Biotest may benefit from strategic collaborations and partnerships with other pharmaceutical companies and research institutions, potentially enhancing its product offerings and market reach. Factors contributing to its earnings include increasing demand for plasma-derived therapies, advancements in production technology, and a growing global focus on personalized medicine.

Biotest Financial Statement Overview

Summary

Biotest has shown revenue growth and improved operational efficiency. However, a decline in net profit margin and increased leverage are concerning. While cash flows have improved, cash conversion efficiency remains a challenge. The overall financial health is stable but with risks.

Income Statement

Biotest has shown a positive revenue growth from 2019 to 2024 with a compound annual growth rate. The gross profit margin improved significantly from the previous years but remains moderate. However, the net profit margin has fallen drastically in 2024 compared to 2023, indicating decreased profitability. The EBIT and EBITDA margins have shown improvement over the years, indicating better operational efficiency.

Balance Sheet

The debt-to-equity ratio has increased, indicating higher leverage, which could pose financial risk. The return on equity (ROE) declined in 2024 due to lower net income. The equity ratio has improved modestly, reflecting a stable capital structure.

Cash Flow

Free cash flow turned positive in 2024, showing improvement in cash management. However, the operating cash flow to net income ratio is low, indicating potential issues with cash conversion. The free cash flow to net income ratio has improved but still reflects challenges in converting income into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	726.20M	684.60M	516.10M	515.60M	484.20M
Gross Profit	223.80M	280.30M	124.90M	80.70M	130.10M
EBITDA	120.40M	179.00M	28.30M	-17.70M	16.00M
Net Income	26.40M	127.00M	-31.60M	-63.30M	-31.40M
Balance Sheet
Total Assets	1.43B	1.41B	1.20B	1.10B	1.13B
Cash, Cash Equivalents and Short-Term Investments	119.50M	118.50M	136.60M	117.50M	89.20M
Total Debt	597.20M	689.80M	574.30M	496.30M	469.10M
Total Liabilities	903.30M	912.00M	831.90M	723.80M	689.70M
Stockholders Equity	530.70M	498.90M	371.10M	380.40M	441.60M
Cash Flow
Free Cash Flow	32.20M	-36.10M	-69.80M	15.70M	-43.70M
Operating Cash Flow	60.90M	-2.70M	-40.50M	33.90M	-16.70M
Investing Cash Flow	-25.70M	1.30M	-37.00M	-23.40M	-14.60M
Financing Cash Flow	-35.40M	-6.80M	89.60M	22.60M	42.00M

Biotest Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 31.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO3, the sentiment is Positive. The current price of 31.6 is above the 20-day moving average (MA) of 31.10, above the 50-day MA of 30.34, and above the 200-day MA of 29.89, indicating a bullish trend. The MACD of 0.29 indicates Positive momentum. The RSI at 54.57 is Neutral, neither overbought nor oversold. The STOCH value of 68.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BIO3.

Biotest Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ILM1	70 Outperform	€333.10M	15.19	4.18%	―	9.27%	65.65%
DMP	65 Neutral	€2.01B	17.31	18.82%	2.43%	0.11%	28.09%
BIO3	64 Neutral	€1.33B	-51.04	―	0.13%	-18.82%	-113.85%
EUZ	64 Neutral	€916.61M	23.05	16.93%	1.15%	9.64%	35.18%
FYB	63 Neutral	€419.73M	-2.48	-34.48%	―	-14.84%	-338.52%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVT	38 Underperform	€917.82M	-5.75	-17.98%	―	-2.67%	7.40%